What the PATINA Trial Teaches Us About Treating HER2+ Breast Cancer
Update: 2025-10-29
Description
Drs. Waks and Lynce review the PATINA trial, which showed that adding a CDK4/6 inhibitor to HER2-targeted and endocrine therapy improved progression-free survival in triple-positive breast cancer, shaping how this subgroup may be managed.
Comments
In Channel



